In Target Discovery's internal discovery programs, we have achieved exceptional reliability and throughput by using UltraTrol(TM) and EOTrol(TM) to separate and quantify alpha 1-antitrypsin
isoforms, critical protein biomarkers for emphysema, liver disorders, and Alzheimer's disease.
announced today the successful completion of a Phase I clinical trial for a recombinant human alpha 1-antitrypsin
(recombinant AAT or rAAT) molecule administered by nebulization.
an Alameda, California-based company developing recombinant alpha 1-antitrypsin
(rAAT) for hereditary emphysema and other respiratory and dermatological indications.
com/ (live and archived) Subjects to be discussed: - Third quarter results (to be announced November 28, 7:30am) - PRDT's prion reduction product announcement (November 19, 2003) - Tunisian project (October 15, 2003) - Arriva-ProMetic phase II clinical study on recombinant Alpha 1-antitrypsin
(rAAT) gel (October 9, 2003) - Strategic alliance with the NRC Biotechnology Research Institute (September 29, 2003)
Its lead indications are for the treatment of hereditary emphysema and asthma using the protein protease inhibitor alpha 1-antitrypsin
(AAT), the prototypic member of the serine protease inhibitor superfamily known as serpins.
is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells.
announced today interim results from its ex vivo human studies of recombinant alpha 1-antitrypsin
(rAAT) in adult and pediatric patients with middle ear disease (otitis media, OM).
These clinical trials, being conducted in the United States, will evaluate the safety, immunogenicity, and tolerability of the jointly developed recombinant alpha 1-antitrypsin
On the heels of last week's announcement of the entering into clinics of recombinant alpha 1-antitrypsin
, ProMetic believes that PBI-1402 will soon follow.
announced today that their joint venture (JV), Arriva-ProMetic Inc, has received approval from the United States Food and Drug Administration and Health Canada to initiate a Phase Ib clinical trial for it's proprietary recombinant alpha 1-antitrypsin
(rAAT) topical gel in patients with atopic dermatitis.
position on recombinant alpha 1-antitrypsin
(rAAT) and other protease
Human alpha 1-antitrypsin
(AAT), a serum glycoprotein, is one of the best-known models of serine protease inhibitors (serpins) superfamily [1, 17].